Clinical Trial Protocol Against Cancer Therapy Side Effects (Mucositis) Approved

Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center’s Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH). This enables the initiation of the clinical trial addressing this significant target at the medical center within a month.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on September 8th, 2008